Maintenance of bronchodilator response for Advair Diskus 250/50 (fluticasone propionate/salmeterol) but not ipratropium/albuterol in patients with COPD

被引：2
|
作者：
Knobil, K [1 ]
Kalberg, C [1 ]
Merchant, K [1 ]
Emmett, A [1 ]
Cicale, M [1 ]
机构：
[1] GlaxoSmithKline, Raleigh, NC USA
来源：
CHEST | 2004年 / 126卷 / 04期
关键词：
D O I：
10.1378/chest.126.4_MeetingAbstracts.807S
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：807S / 807S
页数：1
相关论文
共 50 条
  • [11] The salmeterol/fluticasone propionate (50/250mcg) dry powder combination Diskus® has a faster onset of effect compared with salmeterol or fluticasone propionate in patients with asthma.
    Lumry, W
    Windom, H
    Mendelson, L
    Pedinoff, A
    Prillaman, B
    Baitinger, L
    Woodring, A
    House, K
    Shah, T
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (01) : S132 - S132
  • [12] Effect of fluticasone propionate/salmeterol 250/50 on lung hyperinflation and exercise endurance in patients with COPD
    O'Donnell, DE
    Sciurba, F
    Celli, B
    Mahler, DA
    Webb, K
    Kalberg, C
    Crater, C
    Knobil, K
    CHEST, 2005, 128 (04) : 178S - 178S
  • [13] Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: Response by beta-agonist reversibility
    Bleecker, Eugene R.
    Emmett, Amanda
    Crater, Glenn
    Knobil, Katharine
    Kalberg, Christopher
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2008, 21 (04) : 682 - 688
  • [14] Effects Of Fluticasone Propionate/salmeterol Combination 250/50mcg Bid (advair Diskus™) Vs. Salmeterol 50mcg Bid (serevent Diskus™) On Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Rate, Following Acute Exacerbation Or Hospitalization
    Ohar, J. A.
    Crater, G.
    Emmett, A.
    Ferro, T.
    Morris, A.
    Raphiou, I.
    Sriram, P.
    Dransfield, M. T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [15] Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma.
    Shapiro, G
    Lumry, W
    Wolfe, J
    Given, J
    White, MV
    Woodring, A
    Baitinger, L
    House, K
    Prillaman, B
    Shah, T
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (02) : 527 - 534
  • [16] Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes
    Anzueto, Antonio
    Ferguson, Gary T.
    Feldman, Greg
    Chinsky, Kenneth
    Seibert, Allan
    Emmett, Amanda
    Knobil, Katharine
    O'Dell, Dianne
    Kalberg, Christopher
    Crater, Glenn
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2009, 6 (05) : 320 - 329
  • [17] Improved small airway function with fluticasone propionate/salmeterol versus ipratropium/albuterol therapy in patients with chronic obstructive pulmonary disease (COPD)
    Knobil, K
    Watkins, M
    Merchant, K
    Emmett, A
    Schweiker, S
    Yates, J
    CHEST, 2003, 124 (04) : 165S - 165S
  • [18] Pharmacokinetics and pharmacodynamics of inhaled advair (fluticasone propionate/salmeterol) diskus and metered-dose inhalers in adult patients with asthma.
    Mehta, Rashmi
    Kathman, Steven
    Andrews, Susan
    Daley-Yates, Peter
    Beerahee, Misba
    Kunka, Robert
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1069 - 1069
  • [19] Advair Diskus -: Fluticasone propionate and salmeterol inhalation powder -: Glaxo Wellcome -: Steroid/beta2-agonist combination for maintenance treatment of asthma
    不详
    FORMULARY, 2000, 35 (11) : 871 - 871
  • [20] High satisfaction with fluticasone propionate/salmeterol via diskus reported during experience program in patients with COPD
    Stoloff, S
    Samuels, S
    Braman, S
    Brown, C
    Kerney, D
    Cicale, M
    CHEST, 2005, 128 (04) : 260S - 260S
12345